Literature DB >> 26370422

Concurrent chemo-radiotherapy in elderly patients: tolerance and compliance in a series of 137 patients.

M Di Genesio Pagliuca1, C Perotti1, G Apicella1, A Galla1, M Guffi1, M Paolini1, L Donis1, V Amisano1, S Torrente1, I Manfredda1, M Krengli2.   

Abstract

INTRODUCTION: Aggressive cancer treatment is a challenge in elderly patients. The present study aims to assess tolerance in terms of acute toxicity and compliance of concurrent chemo-radiotherapy (cCRT) in a series of patients aged ≥70 years.
MATERIALS AND METHODS: Clinical records of patients aged ≥70 years who underwent cCRT between January 2005 and December 2013 were reviewed. Concurrent CRT had curative intent in 134 patients (97.8 %) and palliative intent in 3 patients (2.2 %). Chemotherapy (CT) drugs and schedule were selected according to tumor histology. Radiotherapy median dose was 45.0 Gy (range 11-70 Gy) for curative purposes and 54 Gy (range 40-56 Gy) for palliative purposes. Incidence of acute toxicity and compliance to cCRT were analyzed and correlated with age, Karnofsky Performance Status (KPS), and Charlson Comorbidity Index (CCI).
RESULTS: Overall, 137 patients, 82 males (60 %) and 55 females (40 %), median age 74 years (range 70-90 years) were analyzed. Concurrent CRT schedule was completed by 132 patients (96.4 %). Thirty-one of these patients (23.5 %) temporarily interrupted treatment. Hematological toxicity with grade ≥1 was observed in 25 patients (18.2 %), gastrointestinal toxicity in 55 (40.1 %), and genitourinary in 13 (9.5 %). Mucositis with grade ≥1 was recorded in 19 patients (13.9 %). No statistical significant correlation between KPS, CCI, and toxicity was found. A correlation trend between mucositis and patient age (p = 0.05) was observed.
CONCLUSION: Concurrent CRT for elderly was feasible and quite well tolerated. Great attention in prescribing CT dose should be paid to limit acute toxicity.

Entities:  

Keywords:  Chemo-radiotherapy; Compliance; Elderly; Toxicity

Mesh:

Year:  2015        PMID: 26370422     DOI: 10.1007/s12094-015-1403-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  26 in total

1.  Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly.

Authors:  Stephanie A Michal; David J Adelstein; Lisa A Rybicki; Cristina P Rodriguez; Jerrold P Saxton; Benjamin G Wood; Joseph Scharpf; Denise I Ives
Journal:  Head Neck       Date:  2011-10-22       Impact factor: 3.147

2.  Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications.

Authors:  Takeshi Kodaira; Nobukazu Fuwa; Kazuhisa Furutani; Hiroyuki Tachibana; Takuya Yamazaki
Journal:  Jpn J Clin Oncol       Date:  2005-04       Impact factor: 3.019

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  EORTC elderly task force position paper: approach to the older cancer patient.

Authors:  A G Pallis; C Fortpied; U Wedding; M C Van Nes; B Penninckx; A Ring; D Lacombe; S Monfardini; P Scalliet; H Wildiers
Journal:  Eur J Cancer       Date:  2010-03-12       Impact factor: 9.162

5.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

6.  Curative external beam radiotherapy in patients over 80 years of age with localized prostate cancer: a retrospective rare cancer network study.

Authors:  Tan Dat Nguyen; David Azria; Daniele Brochon; Philip Poortmans; Robert C Miller; Luciano Scandolaro; Wojciech Majewski; Marco Krengli; Ufuk Abacioglu; Luigi Moretti; Salvador Villa; Fadil Akyol; Nicolas Jovenin
Journal:  Crit Rev Oncol Hematol       Date:  2009-05-05       Impact factor: 6.312

7.  Elderly patients aged 65-75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide.

Authors:  C Gzell; H Wheeler; L Guo; M Kastelan; M Back
Journal:  J Neurooncol       Date:  2014-05-15       Impact factor: 4.130

8.  Prognostic importance of comorbidity in a hospital-based cancer registry.

Authors:  Jay F Piccirillo; Ryan M Tierney; Irene Costas; Lori Grove; Edward L Spitznagel
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272

Review 9.  Treatment of glioblastoma in elderly patients: an overview of current treatments and future perspective.

Authors:  Gaetano Lanzetta; Giuseppe Minniti
Journal:  Tumori       Date:  2010 Sep-Oct

10.  Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes.

Authors:  David Tougeron; Hadji Hamidou; Michel Scotté; Frédéric Di Fiore; Michel Antonietti; Bernard Paillot; Pierre Michel
Journal:  BMC Cancer       Date:  2010-09-24       Impact factor: 4.430

View more
  2 in total

1.  Factors predicting intolerance to definitive conventional radiotherapy in geriatric patients.

Authors:  Chai Hong Rim; Won Sup Yoon; Jung Ae Lee; Dae Sik Yang; Nam Kwon Lee; Young Je Park; Chul Yong Kim
Journal:  Strahlenther Onkol       Date:  2018-05-24       Impact factor: 3.621

Review 2.  Management of locally advanced rectal cancer in the elderly: a critical review and algorithm.

Authors:  Lara Hathout; Nell Maloney-Patel; Usha Malhotra; Shang-Jui Wang; Sita Chokhavatia; Ishita Dalal; Elizabeth Poplin; Salma K Jabbour
Journal:  J Gastrointest Oncol       Date:  2018-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.